EnBiotix Inc. is discovering compounds that make infections more susceptible to existing antibiotics either by increasing the bacterias' production of reactive oxygen species, or by activating their metabolic pathways. The company is aiming for a discovery alliance followed by an A round that will help fund development of its candidates.

EnBiotix's discovery programs are based on the work of Boston University's James Collins, whose lab has used systems biology approaches to study bacterial responses to antibiotics. Collins is a professor of biomedical engineering at the university, a founding core member of the Wyss Institute for Biologically Inspired Engineering at Harvard University and a Howard Hughes Medical Institute investigator.